Awaiting development: Guidance and quality standards

Showing 131 to 140 of 313

Guidance and quality standards awaiting development
Title	Type
Inebilizumab for treating immunoglobulin G4-related disease [TSID12107]	Technology appraisal guidance
Infant, children and young people's experience of health care	Quality standard
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]	Technology appraisal guidance
Interventional Correction of Superior Sinus Venosus Defect and Partial Anomalous Pulmonary Venous Drainage	Interventional procedures guidance
Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset [TSID10190]	Technology appraisal guidance
Invoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]	Technology appraisal guidance
Iptacopan for treating primary IgA nephropathy [ID6640]	Technology appraisal guidance
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]	Technology appraisal guidance
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949]	Technology appraisal guidance
Isatuximab in combination for maintenance treatment of newly diagnosed multiple myeloma after an autologous stem cell transplant [ID6639]	Technology appraisal guidance